Brookline Capital Markets Forecasts MNPR Q1 Earnings

Key Points

• Brookline Capital Markets raised its Q1 2026 EPS estimate for Monopar to ($0.80) (from ($0.81)) and models quarterly EPS around ($0.80)–($0.82) with a FY2026 loss of ($3.23).
• Monopar recently reported Q1 EPS of ($0.61), missing analysts' consensus of ($0.51) by $0.10.
• Despite the miss, the stock trades near $52 while analysts hold a consensus Buy rating with a $107 price target and the company has a market cap of about $349 million.

Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - Equities research analysts at Brookline Capital Markets increased their Q1 2026 EPS estimates for Monopar Therapeutics in a research report issued on Monday, March 30th. Brookline Capital Markets analyst K. Dolliver now expects that the company will earn ($0.80) per share for the quarter, up from their prior estimate of ($0.81). The consensus estimate for Monopar Therapeutics' current full-year earnings is ($1.65) per share. Brookline Capital Markets also issued estimates for Monopar Therapeutics' Q2 2026 earnings at ($0.80) EPS, Q3 2026 earnings at ($0.81) EPS, Q4 2026 earnings at ($0.82) EPS and FY2026 earnings at ($3.23) EPS.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last announced its earnings results on Friday, March 27th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.10).

Several other equities analysts have also weighed in on the stock. Cantor Fitzgerald restated an "overweight" rating on shares of Monopar Therapeutics in a report on Wednesday, January 21st. Morgan Stanley initiated coverage on shares of Monopar Therapeutics in a report on Friday, January 9th. They issued an "overweight" rating and a $115.00 price objective on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Monopar Therapeutics in a report on Thursday, January 22nd. Wall Street Zen lowered shares of Monopar Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, January 10th. Finally, BTIG Research restated a "buy" rating and issued a $104.00 price objective on shares of Monopar Therapeutics in a report on Monday, February 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $107.00.

Monopar Therapeutics Price Performance

Shares of MNPR stock traded down $1.56 during trading hours on Tuesday, reaching $52.12. 73,935 shares of the company were exchanged, compared to its average volume of 240,813. Monopar Therapeutics has a fifty-two week low of $26.06 and a fifty-two week high of $105.00. The stock's fifty day moving average is $57.59 and its two-hundred day moving average is $70.85. The company has a market cap of $348.66 million, a price-to-earnings ratio of -28.52 and a beta of 1.64.

Institutional Investors Weigh In On Monopar Therapeutics

Hedge funds have recently bought and sold shares of the company. Russell Investments Group Ltd. acquired a new stake in Monopar Therapeutics in the third quarter worth $28,000. BNP Paribas Financial Markets raised its holdings in Monopar Therapeutics by 100.6% in the third quarter. BNP Paribas Financial Markets now owns 696 shares of the company's stock worth $57,000 after purchasing an additional 349 shares during the period. Meeder Asset Management Inc. acquired a new stake in Monopar Therapeutics in the fourth quarter worth $65,000. Caitong International Asset Management Co. Ltd acquired a new stake in Monopar Therapeutics in the fourth quarter worth $86,000. Finally, JPMorgan Chase & Co. raised its holdings in Monopar Therapeutics by 1,821.0% in the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company's stock worth $69,000 after purchasing an additional 1,821 shares during the period. 1.83% of the stock is currently owned by institutional investors and hedge funds.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company's core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company's pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.